Nhin Lu

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy

Targeting Nuclear Receptors with PROTAC degraders

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

Current and future perspectives of liquid biopsies in genomics-driven oncology

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Androgen receptor: structure, role in prostate cancer and drug discovery

Liquid biopsies come of age: towards implementation of circulating tumour DNA

PROTAC targeted protein degraders: the past is prologue

Efficient generation of mouse models of human diseases via ABE- and BE-mediated base editing

Targeted protein degradation by PROTACs

Tumour heterogeneity and resistance to cancer therapies

Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway

Induced protein degradation: an emerging drug discovery paradigm

Transforming targeted cancer therapy with PROTACs: A forward-looking perspective

Tumor clone dynamics in lethal prostate cancer

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft